TEVA — TEVA PHARMACEUTICAL INDUSTRIES LTD
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 818686 ·
Israel
Last close
$36.74
Market Cap
$42.81B
52W High
$37.24
52W Low
$29.60
ADV30
5,506,034
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | 3,981,000,000 | 1,972,000,000 | 759,000,000 | 369,000,000 | 40,040,000,000 | 3,741,000,000 | 31,808,000,000 |
| Dec 2025 | 4,711,000,000 | 2,656,000,000 | 1,269,000,000 | 480,000,000 | 40,748,000,000 | 3,556,000,000 | 32,834,000,000 |
| Sep 2025 | 4,480,000,000 | 2,304,000,000 | 1,075,000,000 | 433,000,000 | 39,856,000,000 | 2,203,000,000 | 32,602,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$1,898,000,000
Investing CF
$39,000,000
Financing CF
$-401,000,000
CapEx
$-550,000,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.60
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$-13,969,000,000
Inventory
$3,221,000,000
Receivables
$3,493,000,000
ST Investments
—
EBIT TTM
$1,605,000,000
Pretax Income TTM
$708,000,000
Interest Exp TTM
$897,000,000
Analysts
10
Yahoo Snapshot (yfinance, live)
Total Revenue
$17,315,000,320
EBITDA
$4,268,000,000
Free Cash Flow
$2,219,875,072
Enterprise Value
$55,753,003,008
Total Cash
$3,655,000,064
Total Debt
$16,894,000,128
Shares Out
1,165,296,084
Trailing EPS
$0.60
Book Value
$6.65
ROE
9.7%
ROA
5.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 17,257,000,000 | 3,952,000,000 | 1,410,000,000 | 40,748,000,000 | 32,834,000,000 | — | 1,649,000,000 |
| Dec 2024 | 16,544,000,000 | 3,364,000,000 | -1,639,000,000 | 39,326,000,000 | 33,606,000,000 | — | 1,247,000,000 |
| Dec 2023 | 15,845,000,000 | 3,194,000,000 | -559,000,000 | 43,479,000,000 | 35,353,000,000 | — | 1,368,000,000 |
| Dec 2022 | 14,925,000,000 | 2,690,000,000 | -2,446,000,000 | 44,011,000,000 | 35,413,000,000 | — | 1,590,000,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$3.08
Max Pain — expiry 2026-08-21
max pain strike: $32.00 · spot: $36.52 · call oi: 36,386 · put oi: 3,630
Expected Move to 2026-08-21:
±$1.37
(3.75%) —
implied range
$35.15 –
$37.89
· ATM straddle on $36.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TEVJF | TEVA PHARMACEUTICAL INDUSTRIES LTD | $43.12B | $37.00 | — |
| ONC | BeOne Medicines Ltd. | $37.44B | $359.05 | — |
| TKPHF | TAKEDA PHARMACEUTICAL CO LTD | $54.69B | $34.25 | — |
| TAK | TAKEDA PHARMACEUTICAL CO LTD | $55.60B | $17.41 | — |
| ZTS | Zoetis Inc. | $30.39B | $73.54 | — |
News headlines (Yahoo Finance, 1h cache)
Teva (TEVA) Q2 2026 Earnings Call Transcript
2026-08-08 00:02 · Yahoo
Why Teva Pharmaceutical Stock Surged This Week
2026-08-02 17:04 · Yahoo
Dear Teva Pharmaceutical Stock Fans, Mark Your Calendars for September 14
2026-08-02 14:14 · Yahoo
Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | Delve
2026-07-30 14:31 · Yahoo
ADAMA Appoints Orly Pascal as Chief Human Resources Officer
2026-08-13 09:59 · Yahoo
Can Amneal's Kashiv Deal Turn Biosimilars Into a Major Growth Engine?
2026-08-12 15:53 · Yahoo
Is AMRX Stock a Buy as Growth Improves but Execution Risks Persist?
2026-08-12 15:51 · Yahoo
AMRX Stock Surges 44.8% in 3 Months: Can the Rally Keep Running Now?
2026-08-12 15:49 · Yahoo
Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy
2026-08-11 12:00 · Yahoo
SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?
2026-08-07 15:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.